GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Parent Inc (NAS:NTEC) » Definitions » Operating Margin %

Intec Parent (Intec Parent) Operating Margin % : 0.00% (As of Mar. 2021)


View and export this data going back to 1996. Start your Free Trial

What is Intec Parent Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Intec Parent's Operating Income for the three months ended in Mar. 2021 was $-4.18 Mil. Intec Parent's Revenue for the three months ended in Mar. 2021 was $0.00 Mil. Therefore, Intec Parent's Operating Margin % for the quarter that ended in Mar. 2021 was 0.00%.

The historical rank and industry rank for Intec Parent's Operating Margin % or its related term are showing as below:


NTEC's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -171.86
* Ranked among companies with meaningful Operating Margin % only.

Intec Parent's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Intec Parent's Operating Income for the three months ended in Mar. 2021 was $-4.18 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2021 was $-14.27 Mil.


Intec Parent Operating Margin % Historical Data

The historical data trend for Intec Parent's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent Operating Margin % Chart

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Operating Margin %
Get a 7-Day Free Trial - - - - -

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Intec Parent's Operating Margin %

For the Biotechnology subindustry, Intec Parent's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intec Parent's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intec Parent's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Intec Parent's Operating Margin % falls into.



Intec Parent Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Intec Parent's Operating Margin % for the fiscal year that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (A: Dec. 2020 ) / Revenue (A: Dec. 2020 )
=-13.829 / 0
= %

Intec Parent's Operating Margin % for the quarter that ended in Mar. 2021 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2021 ) / Revenue (Q: Mar. 2021 )
=-4.178 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intec Parent  (NAS:NTEC) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Intec Parent Operating Margin % Related Terms

Thank you for viewing the detailed overview of Intec Parent's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent (Intec Parent) Business Description

Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397
Nadav Navon officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
R Michael Gendreau officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Gil Bianco director 7 HAORANIM STREET BAZRA L3 60944